Justine Decroocq

The share of this author’s assessed papers carrying a ⚑ flag. A concentration is a prompt for expert review — never, on its own, a determination about the person.

Collaborators, sized by shared output and coloured by their own reproducibility (green = high, red = low). Click a node to open their card. A pattern is a prompt for review, never a determination.

How this author’s assessed papers reproduced — the outcome of reproduction attempts, not a judgement of the person. Coverage is partial and grows over time.

Assessed papers (1)

• Integrated analysis of post-transcriptional regulations reveals insights into acute myeloid leukemia.⚑
  2025 L1 32/100 ⚑

1 assessed by us (0 reproduced) · 135 not yet assessed — every PubMed paper on record, linked below.

• Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series ↗

  Annals of the Rheumatic Diseases · 2026 · PMID 41792022
  not yet assessed
• High frequency of <scp>CD95</scp> ⁺ / <scp>CD45RA</scp> ⁻ regulatory T cells defines an immunosuppressive profile associated with <scp>MDS</scp> progression ↗

  British Journal of Haematology · 2026 · PMID 42080308
  not yet assessed
• Outcomes and salvage strategies for large B‐cell lymphoma progressing after second‐line CAR T‐cell therapy: A DESCAR‐T study from the LYSA group ↗

  HemaSphere · 2026 · PMID 42099680
  not yet assessed
• OC.53 Use of the CD19/CD3 T cell engager blinatumomab in refractory systemic sclerosis: a case series ↗

  2026
  not yet assessed
• CAR T-cell therapy in autoimmune diseases: where are we and where are we going? ↗

  The Lancet Rheumatology · 2025 · PMID 40157379
  not yet assessed
• Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients ↗

  Blood Cancer Journal · 2025 · PMID 40246832
  not yet assessed
• Outcomes of patients with relapsed or refractory primary mediastinal B‐cell lymphoma treated with anti‐CD19 CAR‐T cells: CARTHYM, a study from the French national DESCAR‐T registry ↗

  HemaSphere · 2025 · PMID 39968186
  not yet assessed
• Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines ↗

  European Journal of Cancer · 2025 · PMID 40157284
  not yet assessed
• Late failure of aggressive B-cell lymphoma after CAR T-cell therapy: a LYSA study from the DESCAR-T registry ↗

  Blood Advances · 2025 · PMID 41124667
  not yet assessed
• Exposure to the immune system during bridging radiotherapy for Car-T cells ↗

  Cancer/Radiothérapie · 2025 · PMID 40253845
  not yet assessed
• Molecular profiling and risk stratification in solitary bone plasmacytoma ↗

  Leukemia · 2025 · PMID 40954216
  not yet assessed
• Prevention and management of infectious diseases in pregnant women with haematological malignancies ↗

  The Lancet Haematology · 2025 · PMID 40744046
  not yet assessed
• POS1121 THE USE OF THE CD3/CD19 T CELL ENGAGER BLINATUMOMAB IN SEVERE SYSTEMIC SCLEROSIS: A CASE SERIES ↗

  Annals of the Rheumatic Diseases · 2025
  not yet assessed
• Fatal Grade V Immune Effector Cell–Associated Neurotoxicity Syndrome After Chimeric Antigen Receptor T Cell Therapy Leading to Brain Death ↗

  Neurocritical Care · 2025 · PMID 40102371
  not yet assessed
• Hémopathies malignes associées à la grossesse ↗

  médecine/sciences · 2025 · PMID 40293151
  not yet assessed
• 446 | IMPACT OF RESPONSE TO HOLDING/BRIDGING THERAPY IN SECOND‐LINE DLBCL PATIENTS TREATED WITH AXICABTAGENE CILOLEUCEL: A LYSA STUDY FROM THE FRENCH DESCAR‐T REGISTRY ↗

  Hematological Oncology · 2025
  not yet assessed
• 381 | CD19 CAR‐T CELL THERAPY IN RELAPSED/REFRACTORY SOLID ORGAN TRANSPLANT‐RELATED LYMPHOPROLIFERATION: A LYSA ANALYSIS OF THE FRENCH COHORT DESCAR‐T ↗

  Hematological Oncology · 2025
  not yet assessed
• Pro-inflammatory role of granzyme K producing bystander CD8 ⁺ T cells in acute myeloid leukemia ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2025
  not yet assessed
• MDS BIOLOGY AND PATHOGENESIS - IMMUNE DEREGULATION / INFLAMMATION ↗

  Leukemia Research · 2025
  not yet assessed
• Supplementary Figure 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2025
  not yet assessed
• Supplementary Figure 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2025
  not yet assessed
• Supplementary Table 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2025
  not yet assessed
• Supplementary Table 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2025
  not yet assessed
• Supplementary Table 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2025
  not yet assessed
• Supplementary Table 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2025
  not yet assessed
• Supplementary Figure 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2025
  not yet assessed
• Supplementary Figure 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2025
  not yet assessed
• Excellent outcomes with anti-PD1 therapy in relapsed/refractory primary mediastinal large B-cell lymphoma: Real-world data from the lysa group ↗

  Blood · 2025
  not yet assessed
• Impact of the number of bridging therapy lines on outcomes after axi-cel in LBCL: A lysa study from the descar-T registry ↗

  Blood · 2025
  not yet assessed
• Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries ↗

  Blood · 2025
  not yet assessed
• Validation of the FL/IL6 score, a new dynamic cytokine-based risk-model in adults with acute myeloid leukemia, a prospective multicentre filo study. ↗

  Blood · 2025
  not yet assessed
• Outcome of patients with large B-cell lymphoma relapsing after second-line CAR-t: Insights from the descar-t registry ↗

  Blood · 2025
  not yet assessed
• CAR T-cell therapy in secondary CNS lymphomas: A real-world study from the descar-t registry ↗

  Blood · 2025
  not yet assessed
• Comparison of axi-cel versus liso-cel as 2nd line therapy for relapsed/refractory large B-cell lymphoma in real-life: A lysa study from the descar-T registry ↗

  Blood · 2025
  not yet assessed
• Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: a DESCAR-T Registry and International Collaborative Study ↗

  Blood · 2025
  not yet assessed
• Integrated analysis of post-transcriptional regulations reveals insights into acute myeloid leukemia⚑

  Communications Biology · 2025 · PMID 41407883
  L1 32/100 ⚑
• Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy ↗

  Blood Advances · 2024 · PMID 39163620
  not yet assessed
• Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment ↗

  American Journal of Hematology · 2024 · PMID 38899566
  not yet assessed
• Maternal and obstetric outcomes in women with pregnancy-associated haematological malignancies: an observational nationwide cohort study ↗

  The Lancet Haematology · 2024 · PMID 39389070
  not yet assessed
• Impact of critical illness on continuation of anticancer treatment and prognosis of patients with aggressive hematological malignancies ↗

  Annals of Intensive Care · 2024 · PMID 39259434
  not yet assessed
• High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia ↗

  Blood · 2024 · PMID 38669635
  not yet assessed
• Proton Therapy Reduces the Effective Dose to Immune Cells in Mediastinal Hodgkin Lymphoma Patients ↗

  International Journal of Particle Therapy · 2024 · PMID 39091405
  not yet assessed
• Tolerance of radiotherapy with concomitant glofitamab in diffuse large B cell lymphoma: a case report ↗

  Strahlentherapie und Onkologie · 2024 · PMID 38955824
  not yet assessed
• Biological Findings and Clinical Outcomes in Patients Treated With R‐<scp>CHOP</scp> Plus High‐Dose Methotrexate as First‐Line Therapy in Large B‐Cell Lymphoma With Testis Involvement ↗

  European Journal Of Haematology · 2024 · PMID 39394958
  not yet assessed
• A retrospective comparison of abbreviated course “7+7” vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia. ↗

  Journal of Clinical Oncology · 2024
  not yet assessed
• A Real-World Weighted Comparison of Tisagenlecleucel and Axicabtagene Ciloleucel CAR T Cells in Relapsed or Refractory Diffuse Large B Cell Lymphoma Aged 75 Years and Older : A Lysa Study from the Descar-T Registry ↗

  Blood · 2024
  not yet assessed
• Supplementary Figure 3 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Data from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Supplementary Figure 4 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Supplementary Figure 5 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Supplementary Figure 6 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Supplementary Figure 8 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Supplementary Figure 7 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Supplementary Figure 2 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Supplementary Table 2 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Supplementary Figure 1 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Data from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Supplementary Table 1 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Movie Sup 1.TAS cells have greater migratory capacity than untreated T cells in viable Capan-2 tumors explant. from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Supplementary Table 1 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Supplementary Figure 8 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Supplementary Figure 3 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Supplementary Figure 4 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Supplementary Figure 2 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Supplementary Figure 5 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Movie Sup 1.TAS cells have greater migratory capacity than untreated T cells in viable Capan-2 tumors explant. from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Supplementary Figure 1 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Supplementary Figure 6 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Supplementary Figure 7 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• Supplementary Table 2 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  2024
  not yet assessed
• CAR T-Cells Treatment for Relapsed/Refractory B-Cell Lymphoma Is Effective and Safe in People Living with HIV (PLWH): A Lysa Study from the Descar-T Registry ↗

  Blood · 2024
  not yet assessed
• Dihydroartemisinin-induced ferroptosis in acute myeloid leukemia: links to iron metabolism and metallothionein ↗

  Cell Death Discovery · 2023 · PMID 36928207
  not yet assessed
• FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors ↗

  Cancer Immunology Research · 2023 · PMID 37649096
  not yet assessed
• Predictive Factors of Response to Immunotherapy in Lymphomas: A Multicentre Clinical Data Warehouse Study (PRONOSTIM) ↗

  Cancers · 2023 · PMID 37627056
  not yet assessed
• Clinico‐biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi‐centric observational study ↗

  British Journal of Haematology · 2023 · PMID 37403204
  not yet assessed
• Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study ↗

  Blood · 2023
  not yet assessed
• Oncogenetic-Driven Targeted Therapy for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia : A French ALL-Target Observatory Report ↗

  Blood · 2023
  not yet assessed
• CD19-Targeting CAR T-Cell Therapy in Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Descar-T and US Collaborative Study ↗

  Blood · 2023
  not yet assessed
• Fms-like Tyrosine Kinase 3 Ligand Kinetic Profile Is the Strongest Factor Predicting Refractoriness after Induction and Event-Free Survival in Adults with AML: A Filo Prospective Multicentric Study ↗

  Blood · 2023
  not yet assessed
• Subcutaneous azacitidine maintenance in transplantineligible patients with acute myeloid leukemia: a single-center retrospective study ↗

  Haematologica · 2023 · PMID 36994502
  not yet assessed
• Data from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2023
  not yet assessed
• Supplementary Figure 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2023
  not yet assessed
• Supplementary Table 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2023
  not yet assessed
• Supplementary Table 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2023
  not yet assessed
• Supplementary Table 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2023
  not yet assessed
• Supplementary Table 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2023
  not yet assessed
• Supplementary Table 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2023
  not yet assessed
• Supplementary Figure 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2023
  not yet assessed
• Supplementary Figure 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2023
  not yet assessed
• Supplementary Table 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2023
  not yet assessed
• Supplementary Figure 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2023
  not yet assessed
• Supplementary Table 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2023
  not yet assessed
• Supplementary Table 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2023
  not yet assessed
• Data from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2023
  not yet assessed
• Supplementary Figure 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2023
  not yet assessed
• Supplementary Figure 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  2023
  not yet assessed
• Identification des mutations somatiques et analyse des mécanismes immunologiques au cours des manifestations auto-immunes et/ou inflammatoires associées à la leucémie myélomonocytaire chronique ↗

  La Revue de Médecine Interne · 2023
  not yet assessed
• RCHOP Plus High-Dose Methotrexate As First-Line Therapy in Large B-Cell Lymphoma with Testis Involvement ↗

  Blood · 2023
  not yet assessed
• Prognostic impact of<i>DDX41</i>germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study ↗

  Blood · 2022 · PMID 35443031
  not yet assessed
• AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia ↗

  Cell Reports · 2022 · PMID 34986346
  not yet assessed
• Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients ↗

  Blood Cancer Journal · 2022 · PMID 36055992
  not yet assessed
• Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era ↗

  Viruses · 2022 · PMID 36366475
  not yet assessed
• Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia ↗

  Blood · 2022
  not yet assessed
• Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience ↗

  Clinical Cancer Research · 2022 · PMID 36201165
  not yet assessed
• RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia ↗

  Leukemia · 2022 · PMID 35354920
  not yet assessed
• Pharmaceutical cancer care for haematology patients on oral anticancer drugs: Findings from an economic, clinical and organisational analysis ↗

  European Journal of Cancer Care · 2022 · PMID 36273820
  not yet assessed
• Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO) ↗

  Blood · 2022
  not yet assessed
• Etoposide-containing regimens for the treatment of critically ill patients with hematological malignancy-related hemophagocytic lymphohistiocytosis ↗

  Acta Oncologica · 2022 · PMID 35243961
  not yet assessed
• <scp>PCR‐Fluo‐<i>ASXL1</i>‐FA</scp>: A fast, sensitive and inexpensive complementary method to detect <scp><i>ASXL1</i></scp> mutations in haematological malignancies ↗

  International Journal of Laboratory Hematology · 2022 · PMID 35793805
  not yet assessed
• Therapy related myeloid neoplasms (t-MNs) following PARP inhibitors (PARPi): Real-life experience. ↗

  Journal of Clinical Oncology · 2022
  not yet assessed
• Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience ↗

  Blood · 2022
  not yet assessed
• Etoposide-containing regimens for the treatment of critically ill patients with hematological malignancy-related hemophagocytic lymphohistiocytosis ↗

  Figshare · 2022
  not yet assessed
• APR-246 induces early cell death by ferroptosis in acute myeloid leukemia ↗

  Haematologica · 2021 · PMID 33406814
  not yet assessed
• Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma ↗

  Blood · 2021 · PMID 34905598
  not yet assessed
• Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia ↗

  Leukemia & lymphoma/Leukemia and lymphoma · 2021 · PMID 34405773
  not yet assessed
• Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis ↗

  Blood Cancer Journal · 2021 · PMID 33741892
  not yet assessed
• Management of patients with multiple myeloma in the era of COVID-19 pandemic: how hospital at home changes our medical practice ↗

  Supportive Care in Cancer · 2021 · PMID 34056680
  not yet assessed
• Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patients ↗

  medRxiv · 2021
  not yet assessed
• Malignant histiocytosis with a Langerhans cell subtype: A report on the diagnostic and therapeutic challenge ↗

  Blood Cells Molecules and Diseases · 2021 · PMID 34751149
  not yet assessed
• Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow ↗

  Cell Reports · 2020 · PMID 31968250
  not yet assessed
• How COVID-19 pandemic has changed haematological care ↗

  Research Square (Research Square) · 2020
  not yet assessed
• PKR-like Endoplasmic Reticulum Kinase Mediates Apoptosis Induced By Pharmacological AMP-Activated Protein Kinase Activation in Acute Myeloid Leukemia ↗

  Blood · 2019
  not yet assessed
• Impact thérapeutique des altérations du gène NF1 sur les voies de signalisation dépendant de RAS dans les leucémies aigus méloïdes.

  2019
  not yet assessed
• Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models ↗

  Blood · 2019
  not yet assessed
• Nouvelles approches thérapeutiques dans les leucémies aiguës myéloïdes ayant des mutations des gènes de la voie RAS ↗

  2019
  not yet assessed
• Nouvelles approches thérapeutiques dans les leucémies aiguës myéloïdes ayant des mutations des gènes de la voie RAS ↗

  2019
  not yet assessed
• Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes ↗

  Bone Marrow Transplantation · 2018 · PMID 30082853
  not yet assessed
• RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia ↗

  Leukemia · 2017 · PMID 28914261
  not yet assessed
• Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire ↗

  American Journal of Hematology · 2017 · PMID 29226497
  not yet assessed
• Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition ↗

  Blood · 2015 · PMID 26186940
  not yet assessed
• Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia ↗

  Science Advances · 2015 · PMID 26601252
  not yet assessed
• Allogeneic Hematopoietic Stem Cell Transplantation Offers Similar Outcome after Myeloablative and Sequential Conditioning Regimen in Patients with Primary Refractory or Relapsed Acute Myeloid Leukemia: A Study from the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC) ↗

  Blood · 2015
  not yet assessed
• Rescue Therapy With Romiplostim for Refractory Primary Immune Thrombocytopenia During Pregnancy ↗

  Obstetrics and Gynecology · 2014 · PMID 25004319
  not yet assessed
• Norovirus-related chronic diarrhea in a patient treated with alemtuzumab for chronic lymphocytic leukemia ↗

  BMC Infectious Diseases · 2014 · PMID 24885918
  not yet assessed